Skip to main content
Sanofi India Ltd logo

Sanofi India Ltd — Investor Relations & Filings

Ticker · SANOFI ISIN · INE058A01010 LEI · 335800VFWLEY5V6PYH80 BSE.NS Manufacturing
Open in API
Filings indexed 1,552 across all filing types
Latest filing 2023-10-27 Capital/Financing Update
Country IN India
Listing BSE.NS SANOFI

About Sanofi India Ltd

https://www.sanofi.in

Sanofi India Ltd focuses on the development, manufacturing, and marketing of a wide range of pharmaceutical products and healthcare solutions. The company operates across several therapeutic areas, including diabetes, cardiology, thrombosis, central nervous system disorders, and consumer healthcare. Its product portfolio includes established brands such as Lantus, Allegra, Combiflam, Amaryl, Avil, and Enterogermina. The organization prioritizes chronic disease management and acute care through a combination of prescription medicines and over-the-counter treatments. By integrating global research capabilities with local manufacturing excellence, the company provides specialized medical solutions aimed at improving patient health outcomes and addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release dated October 27, 2023, from Sanofi India Limited, announcing strategic updates including increased R&D investments, cost initiatives, and the intention to separate the Consumer Healthcare Business. It provides detailed information on the company's strategy, financial guidance for 2023, and preliminary outlook for 2024 and 2025. It also mentions an upcoming R&D Day and a Q3 2023 earnings call. The document contains substantive business and financial information but is not a full financial report like an annual or interim report. It is not a transcript, audit report, or regulatory filing. The content is a strategic and financial update aimed at investors and the market, typical of a Capital/Financing Update or strategic business update. Given the detailed strategic and financial outlook information, the best fitting category is Capital/Financing Update (CAP).
2023-10-27 English
Press Release made by Sanofi a promoter of Sanofi India Limited.
Capital/Financing Update Classification · 95% confidence The document is a press release dated October 27, 2023, from Sanofi India Limited, announcing strategic updates including increased R&D investments, cost initiatives, and the intention to separate the Consumer Healthcare Business. It provides detailed information on the company's strategy, financial guidance for 2023, and preliminary outlook for 2024 and 2025. It also mentions an upcoming R&D Day and a Q3 2023 earnings call. The document is not a full financial report but rather a comprehensive strategic and financial update. It is not a simple announcement of a report publication, nor is it a transcript or regulatory filing. The content aligns best with a Capital/Financing Update (CAP) as it discusses capital allocation, investment plans, and strategic financial outlooks. Therefore, the appropriate classification is CAP with high confidence.
2023-10-27 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the issue of duplicate share certificates due to lost or misplaced original certificates. It references compliance with SEBI regulations and provides details of the shareholders and shares involved. There is no financial data, earnings information, management discussion, or report attached or referenced. The document is an announcement related to share certificates, which falls under share capital changes but specifically concerns duplicate share certificates rather than new share issues or capital restructuring. This type of announcement is best classified under Regulatory Filings (RNS) as it is a compliance disclosure to the stock exchanges without substantive financial reporting or capital restructuring details.
2023-10-23 English
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the company has approved issue of Duplicate share ....
Transaction in Own Shares Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the issue of duplicate share certificates due to lost or misplaced original certificates. It references compliance with SEBI regulations and provides details of the shareholders affected. The content is an announcement of a corporate action related to share certificates, not a financial report, management change, or earnings release. It does not contain financial data or results, nor is it a report publication or certification. The closest fitting category is 'Transaction in Own Shares' (POS), as it relates to share certificate issuance which is a form of share capital transaction, specifically the issuance of duplicate shares replacing lost ones.
2023-10-23 English
Board Meeting — SANOFI INDIA LIMITED has informed the Exchange about Board Meeting to be held on 08-Nov-2023 to inter-alia consider and approve the Unaudited Financial results of the Company for the…
Regulatory Filings
2023-10-19 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a formal letter from the company secretary addressed to stock exchanges, informing about an upcoming Board of Directors meeting scheduled for November 8, 2023. The purpose of the meeting is to consider the unaudited financial results for the quarter and nine months ended September 30, 2023. It also mentions the closure of the trading window related to the publication of these results. The document does not contain the financial results themselves, nor detailed financial data or analysis. It is an announcement about a future board meeting and related procedural information, not the actual interim or quarterly report. The document length is short (1946 characters), and it serves as a notification rather than a report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such announcements that do not fit other specific categories.
2023-10-19 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.